Ardelyx Inc. (ARDX)
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
Ardelyx (ARDX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.08 per share a year ago.
Get Your Money Out of These 3 Biotech Stocks Before the End of July
Biotech stocks are known for their high volatility and potential for massive gains. The success in the sector often hinges on progressive and often groundbreaking medical advancements.
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx sues US health department over kidney disease drug
Drugmaker Ardelyx said on Wednesday that it has filed a lawsuit against the U.S. Department of Health and Human Services and the Centers for Medicare and Medicaid Services (CMS) over their plan to include its kidney disease drug in the Medicare payment bundle system.
Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook
Ardelyx declined last week after the company said it will not apply for TDAPA with the CMS for Xphozah to be included in the bundle in 2025. Legislative efforts may provide temporary relief for Xphozah, but its long-term future remains uncertain. The uncertainty around Xphozah put more pressure on Ibsrela to perform in the IBS-C market.
3 Promising Penny Stocks for the Most Astute Investors
Even though they are among the riskiest stocks on the market, investing in some penny stocks can mean a lot of profits. In times of economic uncertainty, penny stock investment can be a lifesaver for investors.
3 Stocks Under $10 With the Potential to Make You a Millionaire
Buying stocks that can make you millions is any investor's dream. That is why some investors consider micro-cap or small-cap stocks trading under $10.
The 3 Best Penny Stocks to Buy in May 2024
Penny stocks are classified as stocks that trade for less than $5 and are typically some of the riskiest stocks on the market. Many deserve their extremely low valuations, and investors avoid them as a result.
